Eagle Genomics Ltd has signed a collaboration agreement with EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), acting on behalf of the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute, to provide Eagle Genomics with access to the know-how of Ensembl project members. This collaboration does not provide any privileged access to the content of the Ensembl database: i.e. Eagle Genomics retains exactly the same access rights as any other user. However this non-exclusive arrangement will facilitate Eagle Genomics’ provision of technical support for commercial users of Ensembl, who will benefit from an increased range and quality of support options. Eagle Genomics is the first company to enter into this kind of arrangement with the Ensembl project.
Ensembl (www.ensembl.org), funded by the Wellcome Trust and jointly run by the Wellcome Trust Sanger Institute and EMBL-EBI, is an open-source data resource that produces and maintains automatic annotation on selected eukaryotic genomes, including a powerful genome browser for browsing the annotations. Genome data forms a key part of biological research as scientists look at the genetics of the organisms they are working on to validate hypotheses and propose new hypothesis. Ensembl’s open-source nature allows it to be deployed universally without restriction and at no financial cost, providing scientists with easy access to a high-quality and well-regarded genome browser tool and supporting data.
The aim of the engagement between Ensembl and Eagle Genomics is to enhance Eagle Genomics capabilities in the provision of commercial grade support offerings based around the Ensembl platform. As a result the company will be able to confidently and expertly provide technical support for developers and users alike, including user training and the development of plugins and modifications. The ongoing collaboration between Eagle Genomics and the Ensembl project will ensure that they will work together on the Ensembl project in an integrated fashion.
Dr. Paul Flicek, leader of the Ensembl project team at EMBL-EBI, said “the collaboration agreement with Eagle Genomics extends the reach of Ensembl to those users that require service level agreements, while benefiting the project through the integration of new features into our open-source platform.”
Abel Ureta-Vidal, CEO of Eagle Genomics Ltd stated that “this collaboration agreement is a great step for the company and one on which both parties have worked towards for many months. As far as Eagle Genomics is concerned, it adds to existing collaboration agreements we have with other academic research institutions. These agreements are the heart of the company business model allowing the company to keep up to date with cutting edge research and academic output for the benefit of our customers.“